Eads & Heald Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Eads & Heald Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$215K	Buy	+345	New	+$235K	0.11%	142

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Eads & Heald Wealth Management's REGN Position: Q2 2026 in Review

Eads & Heald Wealth Management opened a new position in Regeneron Pharmaceuticals (REGN) in Q2 2026: 345 shares worth $215K. The stake represents 0.11% of the portfolio and ranks #142 among its holdings.

1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Eads & Heald Wealth Management held 345 shares of Regeneron Pharmaceuticals worth $215K as of Q2 2026.
Regeneron Pharmaceuticals was a new Eads & Heald Wealth Management position in Q2 2026.
Regeneron Pharmaceuticals made up 0.11% of Eads & Heald Wealth Management's portfolio in Q2 2026, its #142 holding.
1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Eads & Heald Wealth Management's 13F filing for Q2 2026, filed 31 Jul 2026.